Skip to main content

Table 3 Clinical information of the patients included in induced sputum experiments

From: Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease

 

Non-smokers

Smokers

stable COPD

COPD exa

p-value

Total (n)

15

11

17

7

 

Male/Female

11/4

9/2

11/6

5/2

 

Age (years)

57 (6)

51 (6)

61 (8)

61 (7)

 

Pack years

0

31 (10)

40 (15)

35 (7)

p < 0.0001

FEV1 (l)

3.6 (0.6)

3.9 (0.9)

2.2 (0.8)

1.1 (0.7)

p < 0.0001

FEV1 (% of ref)

101 (10)

98 (11)

67 (20)

35 (20)

p < 0.0001

FEV1/FVC (%)

81 (5)

81 (4)

66 (12)

47 (9)

p < 0.0001

DCO (% of ref)

97 (9)

87 (12)

64 (16)

36 (22)

p < 0.0001

DCO/VA (% of ref)

105 (10)

94 (9)

75 (21)

48 (28)

p < 0.0001

  1. Data is shown as mean (SD), as % of reference where applicable. None of the patients with stable disease were on oral or inhaled corticosteroids. The stable COPD represented patients with mild stage 0–I COPD and COPD exa group represented patients with COPD exacerbation as described. Oral corticosteroid and antibiotic had been started to all patients with COPD exacerbation within the last 48 hours. None of the patients were on N-acetylcysteine or vitamins.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us